Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 15/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 5/20 | 0.37 |
| ▸ | MTOR | P42345 | 5/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720090 | 0.90 | PIK3CB (0.44) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B | |
| SCHEMBL14720305 | 0.84 | PIK3CB (0.40) | PIK3CBPIK3CDPIK3CGPIK3CAP2RX7 | |
| SCHEMBL14720240 | 0.80 | PIK3CB (0.41) | PIK3CBPIK3CDPIK3CGPIK3CAP2RX7 | |
| SCHEMBL14720116 | 0.71 | PIK3CB (0.40) | PIK3CBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL15856085 | 0.70 | MAPT (0.35) | — | |
| SCHEMBL14720059 | 0.68 | PIK3CB (0.43) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B | |
| SCHEMBL14720836 | 0.68 | PIK3CB (0.42) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B | |
| SCHEMBL14720207 | 0.66 | PIK3CB (0.44) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B | |
| SCHEMBL14720208 | 0.66 | PIK3CD (0.56) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B | |
| SCHEMBL14720285 | 0.65 | PIK3CB (0.43) | PIK3CBPIK3CDPIK3CGPIK3CAPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CA, PI4K2B | PIK3CB 6/4885PIK3CD 7/4885PIK3CG 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.